ResearcherZhejiang Chinese Medical UniversityNo recent work listed

Zhifang Gui

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper

Papers 2

Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer. Co-author DOI 10.3892/ijo.2016.3772 ↗
Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells. Co-author DOI 10.1186/s12906-015-0640-5 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jian Xu · 2 shared papers, 2015–2017 · strength 0.15
- Paper Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer. DOI 10.3892/ijo.2016.3772 ↗
- Paper Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells. DOI 10.1186/s12906-015-0640-5 ↗
Feng Luo · 1 shared paper, 2017 · strength 0.08
- Paper Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer. DOI 10.3892/ijo.2016.3772 ↗
Xing Liu · 1 shared paper, 2015 · strength 0.06
- Paper Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells. DOI 10.1186/s12906-015-0640-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.